BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

614 related articles for article (PubMed ID: 18084158)

  • 1. Endocrine complications in patients with Thalassaemia Major.
    Toumba M; Sergis A; Kanaris C; Skordis N
    Pediatr Endocrinol Rev; 2007 Dec; 5(2):642-8. PubMed ID: 18084158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF).
    De Sanctis V; Eleftheriou A; Malaventura C;
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():249-55. PubMed ID: 16462705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
    Gamberini MR; De Sanctis V; Gilli G
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of genotype on endocrine complications in thalassaemia major.
    Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
    Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of endocrine complications in beta-thalassaemia major in the Islamic Republic of Iran.
    Karamifar H; Shahriari M; Sadjadian N
    East Mediterr Health J; 2003; 9(1-2):55-60. PubMed ID: 15562733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
    Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
    Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine complications in transfusion dependent thalassaemia in Penang Hospital.
    Ong CK; Lim SL; Tan WC; Ong EE; Goh AS
    Med J Malaysia; 2008 Jun; 63(2):109-12. PubMed ID: 18942294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine complications in thalassaemia major.
    De Sanctis V; Vullo C; Katz M; Wonke B; Hoffbrand VA; Di Palma A; Bagni B
    Prog Clin Biol Res; 1989; 309():77-83. PubMed ID: 2780752
    [No Abstract]   [Full Text] [Related]  

  • 9. Final height and endocrine function in thalassaemia intermedia.
    De Sanctis V; Tangerini A; Testa MR; Lauriola AL; Gamberini MR; Cavallini AR; Rigolin F
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():965-71. PubMed ID: 10091174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and endocrine function in thalassemia major in childhood and adolescence.
    Delvecchio M; Cavallo L
    J Endocrinol Invest; 2010 Jan; 33(1):61-8. PubMed ID: 20203539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth and management of short stature in thalassaemia major.
    Theodoridis C; Ladis V; Papatheodorou A; Berdousi H; Palamidou F; Evagelopoulou C; Athanassaki K; Konstantoura O; Kattamis C
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():835-44. PubMed ID: 10091154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease.
    Fung EB; Harmatz PR; Lee PD; Milet M; Bellevue R; Jeng MR; Kalinyak KA; Hudes M; Bhatia S; Vichinsky EP;
    Br J Haematol; 2006 Nov; 135(4):574-82. PubMed ID: 17054676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
    Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
    Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival and complications in thalassemia.
    Borgna-Pignatti C; Cappellini MD; De Stefano P; Del Vecchio GC; Forni GL; Gamberini MR; Ghilardi R; Origa R; Piga A; Romeo MA; Zhao H; Cnaan A
    Ann N Y Acad Sci; 2005; 1054():40-7. PubMed ID: 16339650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid function in thalassaemia major.
    Senanayake MP; Suraweera SA; Hubert HD
    Ceylon Med J; 1999 Dec; 44(4):166-8. PubMed ID: 10895267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth and puberty in thalassemia major.
    Raiola G; Galati MC; De Sanctis V; Caruso Nicoletti M; Pintor C; De Simone M; Arcuri VM; Anastasi S
    J Pediatr Endocrinol Metab; 2003 Mar; 16 Suppl 2():259-66. PubMed ID: 12729401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Osteopenia in beta-thalassemia major].
    Brändle M; Galeazzi RL; Morant R; Oesterle M
    Schweiz Med Wochenschr; 1996 Nov; 126(44):1867-74. PubMed ID: 8984599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major.
    Belhoul KM; Bakir ML; Saned MS; Kadhim AM; Musallam KM; Taher AT
    Ann Hematol; 2012 Jul; 91(7):1107-14. PubMed ID: 22281991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Growth and endocrine function in major thalassemia].
    Pérignon F; Brauner R; Souberbielle JC; de Montalembert M; Girot R
    Arch Fr Pediatr; 1993 Oct; 50(8):657-63. PubMed ID: 8002739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.